Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

[EX Q]: Paragraph: Two people who had travelled from Congo died in Uganda last week, the World Health Organization said. A three-year-old boy who was sent back to Congo after testing positive for the disease died at the weekend, Congo’s health ministry said. At least another 1,411 people have died in Congo since August in the second worst outbreak of the disease on record. “Happy to inform you all that we got clearance from both Uganda National Council for Science and Technology and National Drug Authority to bring in the Therapeutic treatment for #Ebola patients in the country,” Uganda’s Health Minister, Jane Ruth Aceng, said on Twitter. The treatments approved for shipment to Uganda were Mapp Biopharmaceutical’s ZMapp, Regeneron Pharmaceuticals Inc’s REGN-EB3 and Remdesivir, made by Gilead Sciences, said WHO spokesman Tarik Jasarevic. “The protocols for the fourth being submitted. Logistics underway with MSF support for importation of a few courses about 10 each,” he added in an email. The U.N. health agency has said there have so far been no known cases of Ebola spreading between people in Uganda - all recorded patients had travelled in from Congo. Four experimental therapeutic treatments are already being used in Congo, it added. On Friday, a WHO panel decided not to declare an international emergency over Congo’s Ebola outbreak despite its spread to Uganda, saying such a declaration could cause too much economic harm. “Obviously, the crisis is far from over,” Mark Green, the head of the U.S. Agency for International Development (USAID), told a news conference in Nairobi. Health workers and people who came in contact with infected people began receiving a Merck experimental vaccine in Uganda on Saturday. (This story corrects name of drug in 5th paragraph to REGN-EB3, not Regeneron). Claim: Uganda clears three experimental Ebola treatments, watches for spread.
[EX A]: Health workers have got the all-clear to use three experimental Ebola treatments in Uganda, a week after the deadly disease spread over the border from Democratic Republic of Congo, authorities said on Tuesday.

[EX Q]: Paragraph: "Patients used to pay $10,000 a year for cancer drugs, but now they’re paying $10,000 a month, according to HBO talk show host Bill Maher. That’s a message circulating on Facebook recently, promoted by the ""Bill Maher Fanpage."" A reader asked us to check it out. The quote comes from the Oct. 2 episode of Real Time with Bill Maher, where Maher discussed Turing Pharmaceuticals, the company that jacked up the cost of a life-saving drug from $13.50 to $750 essentially overnight. ""Not that (Turing CEO Martin) Shkreli is unusual for the pharmaceutical industry,"" Maher said on his show. ""Fifteen years ago, cancer drugs cost an average of $10,000 a year. Now it’s $10,000 a month because this cartel owns the U.S. government every bit as much as Mexican drug lords own theirs."" It’s well known that the cost of health care is on the rise, but has the annual cost of cancer drugs really increased so dramatically in just a decade and a half? Maher’s team sent us links to some news articles about the rising cost of cancer drugs, and we tracked down information that speaks to his claim. The best information we could nail down is the cost of anticancer drugs at launch, the initial price when the Federal Drug Administration approves a drug. These are the sticker prices set by the pharmaceutical companies, not the prices patients actually pay out of pocket, which are reduced by insurance payments, patient assistance programs and other discounts. Costs increases, though, are often passed on to consumers. Maher has a point that cancer drug costs are on the rise. We charted the launch costs of cancer drugs the FDA approved since 1999, using a list compiled by Memorial Sloan Kettering Cancer Center. The second half of Maher’s statement -- that cancer drugs now cost about $10,000 a month -- is also on solid ground. Of drugs approved in 2015, the monthly average cost is $11,319. And experts in the field often cite that $10,000 figure themselves. Because many cancer drugs are not administered to patients for a full year, it’s difficult to determine an average annual cost, so the first half of Maher’s statement -- that they cost about $10,000 a year 15 years ago -- is hard to nail down. To his point, though, the monthly cost of a new drug was dramatically lower in 2000 than what it is now at about $4,634. One of the news articles that Maher’s team sent us is an academic article in the Journal of Oncology Practice that supports his statement. The report reads, ""The average cancer drug price for approximately one year of therapy or a total treatment duration was less than $10,000 before 2000."" Maher’s statement is ""in the ballpark,"" if not an understatement, said Rena Conti, a health economist at the University of Chicago who researches cancer drug prices. In a 2015 paper Conti authored with three other leading health economists, she examined the launch cost of anticancer drugs controlled for inflation and the benefit to the patient (how much it prolongs life expectancy). For example, in 1995, anticancer drugs cost $54,100 for an additional year of life, the study found. In 2005, drugs cost $139,100 for the same benefit, and the price grew to $207,000 in 2013. In the United States, pharmaceutical companies set their own drug prices. What’s pushing them to increase the costs? It’s not necessarily that cancer drugs are getting better and are thus worth more. Conti’s research concluded that just about one-fifth of the cancer drug cost increase can be attributed to a better product. There are two primary forces behind annual cancer drug cost increases, Conti said: First, pharmaceutical companies estimate a ""zone of indifference"" -- based on last year’s prices, how much more would buyers be willing to pay? Second, rebates and discounts for drugs have also increased over time, and this creates an incentive for drug companies to increase their costs alongside the discounts. Pharmaceutical companies defend drug price increases by emphasizing that the revenue funds innovative research and that drugs lower overall health care costs by treating illnesses. Because there’s no formal price regulation and competition in the industry is rare, ""It really is a system where there’s no downward pressure on drug prices,"" said Peter Bach, director of the Memorial Sloan Kettering Center for Health Policy and Outcomes in an interview with Fortune. Our ruling Maher said, ""15 years ago, cancer drugs cost an average of $10,000 a year. Now it’s $10,000 a month."" The average annual cost of a drug isn’t easy to calculate, given the way cancer drugs are scheduled; many drugs aren’t used every month for an entire year. So the first half of the statement is hard to verify, though we did find one academic source that cites a similar figure. However, Maher has a point that the cost of cancer drugs has increased dramatically since 2000, when the average monthly price of a cancer drug, when it first hit the market, was about $4,600. In 2015, the monthly cost is over $10,000. Maher’s numbers are a little squishy, but they’re in the ballpark." Claim: 15 years ago, cancer drugs cost an average of $10,000 a year. Now it’s $10,000 a month.
[EX A]: "Maher said, ""15 years ago, cancer drugs cost an average of $10,000 a year. Now it’s $10,000 a month."" The average annual cost of a drug isn’t easy to calculate, given the way cancer drugs are scheduled; many drugs aren’t used every month for an entire year. So the first half of the statement is hard to verify, though we did find one academic source that cites a similar figure. However, Maher has a point that the cost of cancer drugs has increased dramatically since 2000, when the average monthly price of a cancer drug, when it first hit the market, was about $4,600. In 2015, the monthly cost is over $10,000. Maher’s numbers are a little squishy, but they’re in the ballpark."

[EX Q]: Paragraph: “You name it, I’ve had it,” Wright says. “I’m a very hard case.”  Now, patients like Wright are at the forefront of an experiment, under way in Peoria, Illinois, and hundreds of other U.S. cities, that could transform the way doctors, nurses and hospitals deliver care to patients. Amid the barrage of criticism over the rollout of Obamacare, groups known as Accountable Care Organizations (ACOs) are quietly going about the business of testing the potential for healthcare reform. The efforts, born of President Barack Obama’s Affordable Care Act, are part of the biggest experiment yet to fix the costly and error-plagued U.S. healthcare system. The new models of care, which encourage providers to form networks to coordinate care and cut costs, involve close monitoring of the sickest patients to address budding health problems before they cause a costly trip to the emergency room or an extended hospital stay. Providers that succeed in keeping patients healthy and cutting costs are rewarded with a portion of the savings. In Peoria, a city of 116,000 that is often seen as the archetypal middle American community, two hospital systems - OSF Healthcare and UnityPoint Health - are taking on the challenge. Progress so far is largely anecdotal, but early data showing declines in readmissions and emergency room visits offers a tantalizing glimpse into the potential for reform. Still, there are no guarantees that the savings will exceed the costs. OSF is in its second year of participating in the federal Pioneer Accountable Care Organization, a pilot program involving 32 hospital systems across the country that aims to improve quality while cutting costs in the government’s Medicare insurance program for the elderly. The program rewards doctors and medical centers that show gains on 33 measures of quality, including routine cancer and depression screenings, while still managing to cut overall costs. In its first year, 13 hospitals reported savings. OSF was not one of them, but it came close. The Centers for Medicare and Medicaid Services has not allowed providers to disclose their full first-year results, but Tara Canty, chief operations officer of OSF’s Accountable Care Organization, said the hospital system saw a 30 percent drop in emergency room admissions and a 20 percent drop in inpatient stays among Medicare participants. Canty sees the first two years as a learning process but says she will be “upset personally” if OSF is not achieving savings by year three. Dr. Keith Knepp, chief information officer at UnityPoint Health-Methodist, says reforms are needed, but he sometimes finds it hard to stay optimistic. “Will there be reimbursement to reward the improved quality, or will we spend more money to take in less?”  Success may depend on controlling costs among high-use patients like Wright. She is among the 5 percent of OSF patients who consumes more than 50 percent of the care delivered by the system. Wright spends most of her days in her tidy home in Mackinaw, outside Peoria, tooling around in a motorized wheelchair. Her legs swell up, making her prone to blood clots. Two years ago in November, she had a major complication from her blood thinner drug, Coumadin. “My brain started bleeding. They had to drill holes in my head,” Wright recalls of the ordeal, which kept her in the hospital for nearly a month. “I nearly died twice.”  Wright was among the first of OSF’s Pioneer patients to be assigned a care manager, a nurse charged with keeping her healthy and out of the hospital. “The theory here is if you focus on the people with chronic disease who are your highest utilizers of care … and make a better outcome for those patients, you are able to invest that savings into some of the care for the larger population of patients,” said Michelle Conger, OSF’s chief strategy officer. Like most providers across the country, Peoria’s hospitals have been hit by federal budget cuts and burdened by an outdated reimbursement system focused on how many services they perform rather that quality. OSF, a system of eight acute-care hospitals with $6 billion in annual patient revenue, needs to cut $200 million over the next five years in response to reimbursement cuts from Medicare and other payers. It has adopted the ACO model to help it get there. An actuarial firm is combing through claims data for the 34,000 Medicare patients in OSF’s ACO to help identify patients like Wright, whose high-risk conditions are likely to require more emergency room visits or admissions. The system assigned 35 care managers to work with these patients and come up with ways to prevent more acute health crises. Sometimes that means simply helping patients keep track of their medications or arranging transportation to a pharmacy, said Priscilla Romans, a nurse who works in OSF’s call center. It also means routine checks on high-risk patients. During a call last month, a heart failure patient complained of shortness of breath and a headache. Romans asked whether she could put her shoes on that day. She was only able to get one on, a sign of fluid buildup, and she couldn’t wear her rings. Romans had the woman take her blood pressure, which was too high, and reported the findings to her doctor. The physician doubled the patient’s dose of Lasix to cut the swelling in her hands and feet, and started her on a blood pressure medication. When Romans called the next day, a Friday, the woman felt much better. Romans believes the time she spent on the phone with this patient helped avert a much more costly ER visit. Often, the issues driving health costs are social. In one case, OSF discovered that a patient who kept getting readmitted to the hospital for emphysema had not been taking her medication. “She was squirreling away her money to fix her roof,” said Dr. Stephen Hippler, OSF’s senior vice president for clinical excellence. The Catholic hospital system tapped into a charity program and made the repairs. UnityPoint Health-Methodist, Peoria’s second-biggest provider, has been taking part in Medicare’s Shared Savings ACO, a transitional program in which hospitals assume less risk than in the Pioneer ACO but have fewer potential rewards. The hospital has cared for about 10,000 Medicare ACO patients since July 2012. In November, UnityPoint acquired the 220-bed Procter Hospital, Peoria’s third-largest provider, giving it access to new addiction recovery services and skilled nursing care. The Procter deal follows Methodist’s decision in 2011 to join Iowa-based UnityPoint Health, the 13th-largest non-profit health system in the United States with annual revenue of $2.7 billion. The moves are part of a national consolidation trend among hospitals trying to fill out their menu of services and bring costs under centralized control. “There is a need for size and scale in the new environment,” said Terry Waters, vice president for strategy and development at UnityPoint Health. “You have to be able to diversify your financial risk over a larger patient population.”  According to the Henry J. Kaiser Family Foundation, an estimated 14 percent of the U.S. population is covered by some form of accountable care organization, including 4 million Medicare beneficiaries. OSF could not say whether it has saved money on Wright’s care in the two years since she has been in care management because the system does not release financial information about individual patients. But Canty said the system “has seen significant and sustained declines in the cost of care for patients in care management.”  As for Wright, she appreciates the quick access she now has to her doctors, but she still needs a lot of care. In May, a hip implant had become infected and had to be replaced. While recovering, Wright developed a bothersome cough that turned out to be pulmonary fibrosis, a dangerous scarring of the lungs. “Between May 21 and July 19, I had been released and admitted five times. Five times! It was dreadful.”  Romans, who has helped coordinate some of Wright’s care, said her job is to try to keep patients out of the hospital, but that’s not always possible. “Here we are trying to be financially prudent with our dollars, but the patient needed the care.”  Now, the goal is to stretch out the period between visits. Wright went from July to September with only one hospitalization. “It was quick. She went back home, and she hasn’t been back to the hospital since,” Romans said. Claim: Health reform's grand experiment: Will it play in Peoria?.
[EX A]:
By all accounts, Sandy Wright of Mackinaw, Illinois, is a challenging patient. The spunky 69-year-old with a rare autoimmune disease has been in the hospital more than a dozen times since she was first diagnosed in 1997.